What is the best approach to manage an adult patient with anemia (Hemoglobin 7.7 g/dL), elevated ferritin (535 ng/mL), Iron 29, Total Iron-Binding Capacity (TIBC) 117, and Transferrin Saturation (Tst) 17%?

Management of Anemia with Elevated Ferritin and Low Transferrin Saturation

This patient has anemia of chronic disease (ACD) with functional iron deficiency, not simple iron deficiency anemia—the elevated ferritin (535 ng/mL) with low TIBC (117) and low transferrin saturation (17%) indicates iron sequestration from inflammation, and the priority is identifying and treating the underlying inflammatory or chronic disease process before considering iron supplementation. 1, 2

Understanding the Laboratory Pattern

Your patient's iron studies reveal a critical diagnostic pattern:

• Low hemoglobin (7.7 g/dL) indicates significant anemia requiring urgent attention 3
• Elevated ferritin (535 ng/mL) suggests either iron overload OR acts as an acute-phase reactant in inflammation 4, 1
• Low TIBC (117) is the key finding—this indicates chronic inflammation, liver disease, or chronic disease rather than simple iron deficiency (where TIBC would be elevated) 1, 2
• Low transferrin saturation (17%) paradoxically suggests functional iron deficiency despite high ferritin 4, 5

This combination represents functional iron deficiency where iron is trapped in macrophages and hepatocytes due to hepcidin upregulation from inflammation, making it unavailable for erythropoiesis despite adequate total body iron stores. 2, 6

Immediate Diagnostic Workup Required

Essential Tests to Order Now:

• C-reactive protein (CRP) to confirm and quantify inflammation 1, 2
• Complete metabolic panel including liver function tests and creatinine to assess for chronic kidney disease or liver disease 7, 8
• Reticulocyte count to assess bone marrow response 5
• Peripheral blood smear to evaluate red cell morphology 3
• Vitamin B12 and folate levels as combined deficiencies are common 1
• Thyroid function tests as hypothyroidism can contribute to anemia 8

Investigation for Underlying Causes:

• Gastrointestinal evaluation: In adults with new unexplained anemia, bidirectional endoscopy (gastroscopy and colonoscopy) should be performed to exclude GI malignancy and other pathology 3
• Celiac disease screening (tissue transglutaminase antibodies) as it is found in 3-5% of IDA cases 3
• Urinalysis to exclude hematuria 3
• Age-appropriate cancer screening given the severity of anemia 3
• Assessment for chronic infections, autoimmune disorders, or malignancies that drive inflammatory anemia 2

Management Algorithm

Step 1: Address the Underlying Disease FIRST

Treating the primary inflammatory or chronic condition is paramount—iron supplementation or erythropoiesis-stimulating agents are secondary interventions that will be ineffective unless the underlying disease is controlled. 1, 2

Step 2: Determine if Iron Supplementation is Appropriate

Iron should only be considered if ferritin is <500 ng/mL AND transferrin saturation is <30% according to chronic kidney disease guidelines. 7, 4

In your patient:

• Ferritin is 535 ng/mL (just above the threshold)
• Transferrin saturation is 17% (well below 30%)

This creates a clinical dilemma. The KDIGO guidelines suggest caution with iron when ferritin exceeds 500 ng/mL to avoid iron overload, yet the low transferrin saturation indicates functional iron deficiency. 7, 4

Step 3: Iron Therapy Decision

If you proceed with iron therapy (after addressing underlying disease):

• Intravenous iron is strongly preferred over oral iron in the setting of inflammation, as hepcidin upregulation blocks intestinal iron absorption 8, 1
• Oral iron is likely to be ineffective and poorly tolerated in this inflammatory state 8
• Do NOT give iron if ferritin rises above 800 ng/mL or transferrin saturation exceeds 50% to avoid iron overload 4
• Monitor iron parameters every 3 months during treatment 4

Available IV iron options include iron sucrose (200 mg maximum per dose), ferric gluconate, ferric carboxymaltose, or ferumoxytol—choice depends on local availability and patient factors. 8

Step 4: Consider Transfusion

With hemoglobin of 7.7 g/dL, red blood cell transfusion should be considered if the patient is symptomatic (extreme weakness, dyspnea, chest pain, hemodynamic instability). 7

However, transfusions should be minimized when possible to:

• Reduce allosensitization risk (especially if transplant candidate) 7
• Avoid transfusion-related complications 7
• Allow time for definitive treatment to work 7

Step 5: Erythropoiesis-Stimulating Agents (ESAs)

ESAs should NOT be first-line therapy and are only considered after:

• Underlying disease is addressed 7, 9
• Iron deficiency is corrected (functional or absolute) 7, 4
• Patient remains anemic despite these interventions 7

ESAs carry risks including thromboembolism and should be used cautiously, particularly in patients with malignancy or history of stroke. 7, 9

Critical Pitfalls to Avoid

• Do NOT assume simple iron deficiency anemia—the low TIBC pattern indicates chronic disease/inflammation, not typical IDA 1, 2
• Do NOT give oral iron expecting a response—inflammation blocks intestinal absorption via hepcidin 8, 1
• Do NOT overlook GI pathology—approximately one-third of adults with unexplained anemia have underlying GI pathology including malignancy 3
• Do NOT continue iron if ferritin exceeds 800 ng/mL—this risks iron overload 4
• Do NOT use ESAs without first optimizing iron status—they will be ineffective and expose the patient to unnecessary risks 7, 4

Monitoring Strategy

• Recheck hemoglobin weekly initially given the severity (7.7 g/dL) 7
• Repeat iron studies (ferritin, transferrin saturation) in 4-8 weeks after initiating therapy 1
• Monitor for response to treatment: A hemoglobin rise of ≥10 g/L within 2 weeks suggests effective therapy 3
• If no response after 6-8 weeks, reassess for tumor progression, inadequate iron, or other causes 9